Agilent SureSelect Human All Exon V6, V6+UTR, and V6+COSMIC
Agilent Technologies has added the SureSelect Human All Exon V6, V6+UTR, and V6+COSMIC to its line of target-enrichment products. The new products are designed to address the limitations of exome sequencing, targeting hard-to-capture and multi-mapping regions. The products also increase the sensitivity of variant calling and minimize false negative calls, Agilent said.
The new products are compatible with the custom design capabilities of SureDesign, the sample quality control provided by the Agilent 2100 Bioanalyzer and 2200 Tapestation, the reproducible performance of the Bravo Automated Liquid Handling Platform, and the guided analysis workflows enabled by SureCall software.
Bruker MALDI Tissuetyper, MALDI PharmaPulse, and Mycobacteria Library 3.0
Bruker this week launched three new products at the American Society for Mass Spectrometry and American Society for Microbiology conferences.
The Bruker Maldi Tissuetyper application on Bruker rapifleX MALDI-TOF mass spec system is designed for MALDI imaging anatomical pathology research. The solution works up to 20 times faster than traditional MALDI-TOF systems, using Bruker's proprietary smartbeam 3D laser, the company said. This laser is synchronized with the movement of the MALDI target stage, and has a repetition rate of 10 kHz, enabling higher throughput where researchers have dramatically increased flexibility in pixel size or target tissue size. Depending on sample size, typical tissue sections can now be imaged in approximately 30 minutes, while mass spec images from small tissue biopsies are available in a few minutes, the company said.
Meantime, Bruker's MALDI PharmaPulse solution combines Bruker's MALDI-TOF systems with high-throughput screening robotics and automation software from HighRes Biosolutions to help pharmaceutical, biotech, and contract research customers accelerate drug discovery and development.
Finally, Bruker released the 3.0 expansion of its Mycobacteria Library for research use only on the MALDI Biotyper system. The new library now includes 149 different species, enabling significantly improved rapid and accurate identification of almost all described Mycobacteria species, the company said.
OpGen has launched an expanded molecular testing and bioinformatics program for detecting and managing gram-negative multi-drug resistant organisms (MDRO). The products and services that the company is offering through its program are designed to help healthcare providers identify and treat infected patients.
Specifically, the company is offering its Acuitas suite of MDRO tests and its Acuitas Lighthouse MDRO management system. The company's Acuitas Resistome test detects approximately 50 antibiotic resistance genes in gram-negative bacteria, while its Acuitas whole-genome sequence analysis service provides high-resolution strain typing and subtyping for a full spectrum of resistance genes. The company has also released an early iteration of its Acuitas Lighthouse MDRO management system, which provides molecular information about patients' resistance profiles and integrates that data with other patient and hospital-wide data to help improve overall patient outcomes and reduce hospital costs. OpGen expects to launch a full web-based version of the Lighthouse management system in the third quarter of 2015.
These new products and services are available from OpGen's CLIA testing laboratory.
For more recently launched products and services, please see the New Products page on our website.